Galapagos NV

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 06 aug 2015 - 07:36

Statutaire naam Galapagos NV

Titel Patient recruitment completed in FITZROY Phase 2 Crohn's disease study with filgotinib

Bericht First selective JAK1 inhibitor in Phase 2 in Crohn's disease 175 patients randomized for 20 weeks of treatment Topline primary endpoint data expected in December 2015 Mechelen, Belgium; 6 August 2015 - Galapagos NV (Euronext & NASDAQ: GLPG) announced that the last patient has been randomized in the FITZROY Phase 2 clinical study. The study evaluates the efficacy and safety of filgotinib, a selective JAK 1 inhibitor, during 20 weeks of treatment in 175 patients with Crohn's disease. Galapagos is eligible to receive $50 M fee from AbbVie if AbbVie elects to in-license filgotinib after receipt of the full RA DARWIN 1 and 2 data and elects to move forward with filgotinib in Crohn's disease.

Vorige register resultaat

Volgende register resultaat

Gerelateerde downloads

201508060000000010_Galapagos rondt werving van patiënten af in FITZROY Fase 2 studie met filgotinib in de ziekte van Crohn.pdf (opens in a new window)

201508060000000010_Patient recruitment completed in FITZROY Phase 2 Crohn's disease study with filgotinib.pdf (opens in a new window)

Datum laatste update: 22 december 2025